SCHEMBL2203149

SCHEMBL2203149

Cc1nn(-c2ccc(OC(F)(F)F)cc2)c(C)c1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.55
MAPK1 P28482 1/20 0.55
MAPT P10636 3/20 0.54
RAB9A P51151 3/20 0.54
NPSR1 Q6W5P4 1/20 0.54
PDE4D Q08499 3/20 0.54
NPC1 O15118 2/20 0.54
CACNA2D1 P54289 1/20 0.46
CACNA2D2 Q9NY47 1/20 0.46
NR3C1 P04150 3/20 0.46
POLB P06746 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
LMNA P02545 1/20 0.45
ALKBH1 Q13686 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2200191 0.86 RAB9A (0.57) ALDH1A1MAPTRAB9ANPSR1PDE4D
SCHEMBL2201823 0.86 PDE4D (0.75) ALDH1A1MAPK1MAPTRAB9ANPSR1
SCHEMBL2200520 0.83 ALDH1A1 (0.49) ALDH1A1MAPK1MAPTRAB9ANPSR1
SCHEMBL28691702 0.81 MAPT (0.51) MAPTRAB9ANPSR1PDE4DNPC1
SCHEMBL2857382 0.80 LMNA (0.53) MAPTRAB9ANPSR1PDE4DNPC1
SCHEMBL19119835 0.80 CACNA2D1 (0.52) ALDH1A1MAPK1MAPTRAB9APDE4D
SCHEMBL7551113 0.79 ALDH1A1 (0.83) ALDH1A1MAPK1MAPTRAB9ANPSR1
SCHEMBL2938583 0.78 MEN1 (0.69) MAPTRAB9ANPSR1PDE4DNPC1
SCHEMBL19119834 0.77 CACNA2D1 (0.50) ALDH1A1MAPK1MAPTRAB9APDE4D
SCHEMBL6070720 0.77 PDE4D (0.68) MAPTRAB9ANPSR1PDE4DNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
CN-101765430-A Novel pyrazole derivatives HOFFMANN LA ROCHE 2010-06-30 CN disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 ALDH1A1 1476/4885MAPK1 868/4885MAPT 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.